Dergiler / European Journal of Rheumatology / 2019 / Cilt: 6 - Sayı: 2

Survey on transportation and storage of biological therapies by patients

Sayfa
94–97
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Fifty-three percenthad suffered frequent power outages the previous summer, 22% had experienced blackouts longerthan 48 hours; 37% had taken the BT to another house to avoid wasting it, and four (5%) patients haddisposed of the drug due to a prolonged power outage.Conclusion: Upon prescribing BTs, it is imperative that physicians brief patients on the relevance ofsuitable transportation and storage methods, and a treatment failure should prompt a thorough assessment of transportation and storage conditions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To assess key aspects of transportation and storage of biological therapies (BTs) on thepart of the patients, from the time they collect them from the pharmacy up until the moment ofadministration.Methods: This was a cross-sectional study in the form of a survey completed by outpatients older than18 years who were administered BTs.
📊
Temel Bulgular & Veri:The survey was carried out by the authors between August 2016and January 2017.Results: A total of 83 outpatients were interviewed (mean age, 53; standard deviation, 15; 76% female).Sixty percent had rheumatoid arthritis, 24% had psoriatic arthritis, and 16% sustained other rheumatic and inflammatory diseases.
💡
Sonuç & Katkı:Fifty-three percenthad suffered frequent power outages the previous summer, 22% had experienced blackouts longerthan 48 hours; 37% had taken the BT to another house to avoid wasting it, and four (5%) patients haddisposed of the drug due to a prolonged power outage.Conclusion: Upon prescribing BTs, it is imperative that physicians brief patients on the relevance ofsuitable transportation and storage methods, and a treatment failure should prompt a thorough assessment of transportation and storage conditions.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:2017 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: To assess key aspects of transportation and storage of biological therapies (BTs) on thepart of the patients, from the time they collect them from the pharmacy up until the moment ofadministration.Methods: This was a cross-sectional study in the form of a survey completed by outpatients older than18 years who were administered BTs. The survey was carried out by the authors between August 2016and January 2017.Results: A total of 83 outpatients were interviewed (mean age, 53; standard deviation, 15; 76% female).Sixty percent had rheumatoid arthritis, 24% had psoriatic arthritis, and 16% sustained other rheumatic and inflammatory diseases. Twenty percent had not been informed of the importance of properrefrigeration when they were first prescribed BTs; 77% had acquired the medication at least 7 daysbefore administration; 28% had misplaced the drug in the fridge (65% of them in the freezer); 90%was unaware of the temperature range at which the BT should be kept in the fridge, and only one(1%) of them had once used a thermometer to find out the fridge temperature. Fifty-three percenthad suffered frequent power outages the previous summer, 22% had experienced blackouts longerthan 48 hours; 37% had taken the BT to another house to avoid wasting it, and four (5%) patients haddisposed of the drug due to a prolonged power outage.Conclusion: Upon prescribing BTs, it is imperative that physicians brief patients on the relevance ofsuitable transportation and storage methods, and a treatment failure should prompt a thorough assessment of transportation and storage conditions.

🔖

Bu Makaleye Atıf Yap

SAAVEDRA, M. A., AIMO, C., ANDRADE, J. A., ALVAREZ, D., SEQUEIRA, G., KERZBERG, E. (2022). Survey on transportation and storage of biological therapies by patients. European Journal of Rheumatology, Cilt: 6 - Sayı: 2, 94–97. https://ajindex.com/articles/650457

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Allegra JR, Brennan J, Lanier V, Lavery R, Markenzie B. Storage temperatures of out-of-hospital medications. Acad Emerg Med 1999; 6: 1098- 103. [CrossRef] 2. Tutuncu Z, Kavanaugh A (2017) Anti-cytokine Therapies. In Kelley & Firestein´s Textbook of Rheumatology. Edited by Gary S. Firestein, Sherine E. Gabriel, Iain B. McInnes, James R. O’Dell. Tenth Edition.
  2. Elsevier, Philadelphia, pp: 999- 1019. [CrossRef] 3. ANMAT (2015) Humira/Humira Pen/Adalimumab. Available from: URL: http://www.anmat.gov.ar/boletin_anmat/febrero_2015/Dispo_1711-15.pdf (Accessed 30.01.2018) 4. ANMAT (2013) Cimzia/Certolizumab pegol. Available from: URL. http://www.anmat. gov.ar/boletin_anmat/diciembre_2013/Dispo_7564-13.pdf (Accessed 30.01.2018). 5. ANMAT (2016) Enbrel/ Etanercept. Available from: URL: http://www.anmat.gov.ar/boletin_anmat/Abril_2016/Dispo_3722-16.pdf (Accessed 30.01.2018). 6. ANMAT (2015) Simponi/Golimumab. Available from: URL: http://www.anmat.gov.ar/boletin_ anmat/septiembre_2015/Dispo_7207-15.pdf (Accessed 30.01.2018). 7. ANMAT (2013) Remicade/Infliximab. Available from: URL: http://www.anmat.gov.ar/boletin_anmat/abril_2013/Dispo_2093-13.pdf (Accessed 30.01.2018). 8. ANMAT (2012) Mabthera/Rituximab. Available from: URL: http://www.anmat.gov.ar/boletin_anmat/junio_2012/Dispo_3563-12.pdf (Accessed 30.01.2018). 9. ANMAT (2015) Actemra/Tocilizumab. Available from: URL: http://www.anmat.gov.ar/boletin_ anmat/septiembre_2015/Dispo_7858-15.pdf (Accessed 30.01.2018). 10. ANMAT (2015) Stelara/Ustekinumab. Available from: URL: http://www.anmat.gov.ar/boletin_anmat/enero_2015/Dispo_0101-15.pdf (Accessed 30.01.2018). 11. Regulación de la cadena de Frio de los medicamentos (2009) Medicamentos Ley 26492. Available from: URL: http://www.anmat. gov.ar/webanmat/Legislacion/Medicamentos/Ley_26492_cadenafrio.pdf (Accessed 30.01.2018) 12. Cohen V, Jellinek SP, Teperikidis L, Berkovits E, Goldman WM. Room-temperature storage of medications labeled for refrigeration. Am J Health Syst Pharm 2007; 64: 1711-5. [CrossRef] 13. European Commission (2013) Information from European Union Institutions, Bodies, Offices and Agencies. Guidelines of 5 November 2013 on Good Distribution Practice of Medicinal Products for Human Use. (2013/c 343/01). Available from: URL: https://ec.europa.eu/health/sites/health/ files/files/eudralex/vol1/2013_c343_01/2013_ c343_01_en.pdf (Accessed 30.01.2018). 14. Marco Garbayo JL, Cuellar Monreal MJ, Pérez Castelló I, Castelló Escrivá A, Muelas Tirado J, Pelegrí S